Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
Journal of Korean Medical Science
; : 710-715, 2015.
Article
em En
| WPRIM
| ID: wpr-146129
Biblioteca responsável:
WPRO
ABSTRACT
The aim of the present study was to evaluate the efficacy and toxicity of stereotactic body radiation therapy (SBRT) for low- to intermediate-risk prostate adenocarcinoma. Thirty-nine patients were retrospectively reviewed. The SBRT was delivered using the CyberKnife with the fiducial tracking method combined with In-tempo imaging. The gross target volume, which included the prostate only, was delineated on the fused CT/MRI scans. The prescription dose was delivered every other day as 5 fractions of 7.5 Gy. Venous blood was obtained before and after SBRT to assess the prostate-specific antigen (PSA) level. Toxicity was evaluated using the CTCAE, v4.03. The median follow-up time was 30.0 months. The median initial PSA level was 7.7 ng/mL. PSA levels decreased in all patients treated with SBRT, and after 5 months, the median PSA was less than 2 ng/mL. The rate of overall 3-yr actuarial biochemical failure free survival was 93.9%. Acute side effects were generally comparable with those of previous studies. The PSA change and toxicity after SBRT for low- to intermediate-risk prostate adenocarcinoma indicates favorable biochemical responses and tolerable levels of toxicity. Additionally short course treatment may produce cost benefit and convenience to patients.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Neoplasias da Próstata
/
Dosagem Radioterapêutica
/
Planejamento da Radioterapia Assistida por Computador
/
Adenocarcinoma
/
Resultado do Tratamento
/
Radiocirurgia
/
Medição de Risco
/
Radioterapia Guiada por Imagem
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Journal of Korean Medical Science
Ano de publicação:
2015
Tipo de documento:
Article